The BCDD at the BioMed@TAU Rare Diseases Hub Symposium
The talks focused on in silico prediction of FDA approved drugs for a rare disease
BLAVATNIK CENTER for Drug Discovery presented yesterday its activity at the "Rare Diseases: From Patients to Bench and Back" symposium.
The event was organized by the Research Hub in Rare Diseases at Tel Aviv University in collaboration with the Sheba Medical Center’s Institute of Rare Diseases.
Adva Yeheskel, a research fellow of the Computer-Aided Drug Design Unit at the BCDD, reviewed the BCDD three units, their expertise and contact members. The talk, under the title "Small molecule Design Based on Mutation Analysis - Personalized Medicine Approach", was focused on in silico prediction of FDA approved drugs for a rare disease named STXBP1.